evidence-based pharmacotherapy -...
TRANSCRIPT
![Page 1: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/1.jpg)
Evidence-BasedPharmacotherapy
EmilyHarris,MD,MPH,FAAPCincinnatiChildren’sHospitalMedicalCenter
![Page 2: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/2.jpg)
CMEDisclosure
• IhavenopersonalfinancialrelationshipsinanycommercialinterestrelatedtothisCME.
• Idonotplantoreferenceofflabel/unapprovedusesofdrugsordevices.
![Page 3: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/3.jpg)
Objectives
• ReviewbestpracticesinmedicationmanagementofADHD,depression,anxiety,anddisruptivebehavior
• Discusscommonadverseeffectsandcontraindications/precautions
• Discussapprovedindicationsforandmonitoringofatypicalantipsychotics
![Page 4: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/4.jpg)
![Page 5: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/5.jpg)
Ashleyisan8yearoldgirlreferredforanADHDevaluation.Hermotherdescribesproblemswithinattentionbothathomeandatschool.Sheisin2ndgradeandisstrugglinginschool.Herteachernotesthat“shejustdoesn’tpay
attention.”Shehastroublesittingstillandoftendisruptstheclassroom.Herfamilyisconcernedthattheseissuesareinterferingwithherschool
performance.
![Page 6: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/6.jpg)
Ashleyhasalsomissedseveraldaysofschoolthisyearforstomachpainsandheadaches.
Hermotherhasrecentlytakenanewjob,andtheseabsenceshavebeendifficultforherfamilytomanage.Theywouldliketoget
AshleystartedonADHDmedicationtohelpherinschoolandreducefamilystress.
![Page 7: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/7.jpg)
AssessmentProcess
AAP. Pediatrics. 2011.
PresenceofDSM-VCriteria
EvidenceofImpairment
Behavioralratingscales Clinician
judgment
![Page 8: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/8.jpg)
AssessmentProcess
Importanceofaccuratediagnosis
1. Manyconditionscanmasqueradeas“attentionproblems”
2. ThereisahighdegreeofcomorbidityinchildrenwithADHD
![Page 9: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/9.jpg)
Ashley’sVanderbiltRatingScalesParent Teacher
InattentionHyperactivity/Impulsivity
Totalsymptom score 46 36ODDScreenConductDisorderScreenAnxiety/Depression Screen# AreaswithImpairment 3 2Average PerformanceScore 3.5 3
![Page 10: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/10.jpg)
Pliska etal.JAmAcad ChildAdolesc Psychiatr.2006;45:642-657.
ADHDFirstorDepressionFirst?
![Page 11: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/11.jpg)
Interventions• DefineADHDasachroniccondition
• Identifytargetoutcomes• Usestimulantmedicationsandbehavioraltherapyasindicated
• Monitortreatmentresponsesystematically
AAP. Pediatrics. 2011;128:1007-1022.
AACAP. J Am Acad Child AdolescPsychiatr. 2007;46:894-921.
![Page 12: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/12.jpg)
BehavioralTherapyas1st Choice
• IfADHDsymptomsaremild,minimalimpairment
• Uncertainofdiagnosis• Markeddisagreementaboutdiagnosisor
parentsrejectmedicine• Familypreference
*CombinedmedicationplusbehavioraltherapyleadstoLESSmedicationutilization
![Page 13: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/13.jpg)
StimulantTitrationStrategies• Startlow,reassessandadjust
– Startat¼- ½childweightinkilograms– Youngerchild=smallerinitialdose– Increaseevery1-2weeks
• Goal- Fulltherapeuticeffectseenwithfewestsideeffects
• Finaltherapeuticdoseroughlyweight-based– Methylphenidate1-2mg/kg/day,SEover1mg/kg– Amphetaminesupto1mg/kg/day,SEover0.6mg/kg
• Followupmonthlyuntilstable,thenquarterly
![Page 14: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/14.jpg)
MethylphenidateDosing• MaximumFDAdosingperday(off-label)
– Ritalin®,Methylin®,Methylin ER®,Metadate ER®,RitalinSR®,Metadate CD®,RitalinLA®60mg(100mgfor>50kg)
– Concerta®72mg(108mg)– Focalin®20mg(50mg);FocalinXR®30mg(50mg)– Daytrana®30mg(?)
AACAP. J Am Acad Child Adolesc Psychiatr. 2007;46;89-921
![Page 15: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/15.jpg)
Methylphenidate• Otherconsiderations
– Manylongactingformscanbeopenedandsprinkledonapplesauceorpudding
• Metadate CD®,RitalinLA®,FocalinXR®
– Concerta®capsuleCANNOTbeopened(OROS)– Daytrana®
• Patchisappliedatthehip;maycauseskinirritation
– Quillivant®isanewXRliquidpreparation– Quillichew®
![Page 16: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/16.jpg)
Amphetamine
• Startlow,reassess,andadjustifneeded– Startat5-10mg/day– Increase5-10mg/dayevery1-2weeksiflimitedbenefitsandadverseeffects
– Morepotentthanmethylphenidate,needLESS
Adapted from AACAP. J Am Acad Child Adolesc Psychiatr. 2007;46;89-921.
www.ohiomindsmatter.org
![Page 17: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/17.jpg)
AmphetamineDosing• Therapeuticdosearound0.6mg/kg/day
– SEmorelikelytooccurathigherdoses• MaximumFDAdosingperday(off-label)
– Dexedrine,®Dextrostat,®Adderall,®andDexedrinespansule®40mg/day(60mgif>50kg)
– AdderallXR®30mg(60mgif>50kg)– Vyvanse®70mg(?)
Adapted from AACAP. J Am Acad Child Adolesc Psychiatr. 2007;46;89-921.
![Page 18: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/18.jpg)
Amphetamine
• Otherconsiderations– AdderallXR®andDexedrinespansule®canbeopenedandsprinkled
– Vyvanse®capsulecanbeopenedandcontentsdissolvedinsmallamountofwater(1-2tsp)
– Vyvanse®mayhavedecreasedabusepotentialduetopro-drugdeliverysystem
![Page 19: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/19.jpg)
NeurotransmittersofNon-stimulants
• Norepinephrinereuptakeinhibitor• Atomoxetine(Strattera)
• Alpha2(a) agonists(enhanceNEtransmission)
• Clonidine,Kapvay• Guanfacine (Tenex,Intuniv),moreselectivelybinds
• Dopaminereuptakeinhibitor• Bupropion(Wellbutrin),metaboliteweakNE
![Page 20: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/20.jpg)
Atomoxetine
• Mechanismofaction– Selectivenorepinephrinereuptakeinhibitor
• NEincreasessignalstrengthinPFC• Antidepressantclass=BlackBoxwarning• Mildeffectonanxiety
– Maytakeupto8-12weeksforfulleffect– Pharmacogenomic testingmayassistwithdosing
Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge Press; 2009:329.
![Page 21: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/21.jpg)
AtomoxetineDosing
• Dosingrecommendations– For<70kg:startwith0.5mg/kg/day,thenincreaseto1.2– 1.4mg/kg/dayafter4-7days
• Maxdose1.4mg/kg/dayor100mg(lesserof1.8mg/kd/dayor100mg)
– For>70kg:40mg/day,thenincreaseto80mg/dayafter7days
• Maxdose100mg(increaseafter2-4weeksifneeded)
AACAP. J Am Acad Child Adoles Psychiatr. 2007;46;89-921.
Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge Press; 2009:51-52.
![Page 22: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/22.jpg)
Atomoxetine
• Otherconsiderations– CapsulesCANNOTbeopenedorsplit– CandividedoseBIDtominimizesideeffects– Mustgivedaily– Doseadjustmentinpatientswithimpairedliverfunction
![Page 23: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/23.jpg)
AlphaAgonistsDosing• Guanfacine
– Longacting(Intuniv):startat1mgdaily;• Increase1mgweeklyto6mgmaximumdose[6mgor2mg/4mg]
– Shortacting(Tenex):startat1mgHSor0.5mgBID• Increase1mgweekly,max4mgdaily[1mg/1mg/2mg]
• Clonidine– Longacting(Kapvay®):startat0.1mgHS;0.4mg/daymax
• Increase0.1mgweeklydividedBID– Shortacting(Clonidine):startat0.05mgHS;0.2-4mg/daymax
• Maygive¼tab(0.025mg)AM
![Page 24: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/24.jpg)
AlphaAgonistDosing
• Alpha agonists – blood pressure medication– Slow upward and downward titration– No more than 1 tablet per week– May start with ½ tablet in the evenings to watch for
sedation. If tolerates after 4-7 days, then add ½ morning dose.
– Taper off short acting before trial of long acting
![Page 25: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/25.jpg)
AdverseEffects
• Stimulants– Aggression– Irritability– Socialwithdrawal– Hypertension,tachycardia– Appetitesuppression– Sleepdisturbance
![Page 26: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/26.jpg)
SeriousAdverseEffects
• Contraindication– Mania– Psychosis– Withdrawaldyskinesia
• Precautions– Anxiety– Parentalsubstanceabuse
• Considerations– Tics
![Page 27: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/27.jpg)
AdverseEffects
• Atomoxetine– Suicidalideation– Hypertension,tachycardia– GIupset,appetitesuppression– Behavioralactivation
• Alphaagonists– Hypotension,bradycardia– Sedation,dizziness
![Page 28: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/28.jpg)
Perrin et al. Pediatrics. 2008;122:451-453.
![Page 29: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/29.jpg)
Update on Ashley• AshleyisprescribedConcerta®18mgeachmorning.Atoneweek,nosideeffectsarenoted,butnobenefitsareseen.Concerta®isincreasedto27mg.
• Atonemonth,Ashleyisseenforafollowupvisit.Sheisnowtaking36mgeachmorningafteranotherdoseincrease.
• Vanderbiltquestionnairesareavailableforyourreview.
![Page 30: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/30.jpg)
Vanderbilt Rating ScalesParent Teacher
InattentionHyperactivity/Impulsivity
Totalsymptom score 46→38 36→20ODDScreenConductDisorderScreenAnxiety/Depression Screen# AreaswithImpairment
Average PerformanceScore Considerafternoonshortactingdose
![Page 31: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/31.jpg)
Whatif…• Shedoesn’ttolerateConcerta?
– Considerswitchtoamphetamineproduct
• Symptomsimprovebutpersistatthetopofthedosinginterval?– Considerswitchtoamphetamineproduct
– Ifpreviousmedicationsunsuccessful,consideradjunctivetherapywithnon-stimulant
http://ppn.mh.ohio.gov
![Page 32: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/32.jpg)
Whatif…• Sheisdoingwell,butgettingheadaches?– Selfcare– hydration,rest– Lowerdose,considerdifferentstimulant
• Sheisdoingwell,butlosingweight?– Addcalories,changetimeofpill– ConsiderCyproheptadine/appetiteinducer
– Decreasedose,changestimulant http://ppn.mh.ohio.gov
![Page 33: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/33.jpg)
Pliska etal.JAmAcad ChildAdolescPsychiatr.2006;45:642-657.
ADHDFirstorDepressionFirst?
![Page 34: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/34.jpg)
Cheungetal.Pediatrics.2007;120(5):1313-1326.
![Page 35: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/35.jpg)
SSRI Indications• AnxietyDisorders
– Sertraline(Zoloft®):FDAindicatedage6andupforOCD– Fluoxetine(Prozac®):FDAindicatedOCDage7andup
• Depression– Fluoxetine(Prozac®): FDAindicatedage8andup– Escitalopram(Lexapro®):FDAindicatedage12andup
Whenmoderatetosevereimpairmentispresent
![Page 36: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/36.jpg)
SelectiveSerotoninReuptakeInhibitors(SSRI’s)
SSRI Starting Dose, mg
Increments, mg
Effective Dose, mg
Maximum Dose, mg
Fluoxetine (Prozac®)
2.5, 5 10-20 20-40 60
Sertraline(Zoloft®)
12.5, 25 25 50 200
Escitalopram(Lexapro®)
2.5, 5 5 10 20
Adapted from Cheung et al. Pediatrics. 2007;120(5):e1313-1326.
![Page 37: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/37.jpg)
SSRI’s• Startlow,reassess,andadjustasneeded
– Increasedoseafter1-2weeks,thenmonitor– Maximaleffectivenessafter4-6weeks– Continuefor9-12monthsaftersymptomsresolve– Taperwhendiscontinuingtoavoidwithdrawaleffects
Medicationfordepressionandanxietydisorderscanbeapproachedsimilarly
![Page 38: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/38.jpg)
BLACKBOXWARNING• Issuedin2004afterconcernsaboutanincreaseinsuicidalthinkinginchildrenprescribedSSRI’s
• 24clinicaltrialsreviewed;over4000children• Nocompletedsuicides• Prevalenceofsuicidalthoughts/actions2XhigherinthosetakingSSRIs(2%vs.4%,notsignificantonlytrend)
• Highestriskwasseenin1st 4weeks,thenprotectionbenefitsseen
• Closemonitoringforsuicidalthinkingisrecommended• Phonecontact1-2weeks(nurse,therapist)• Facetofacewithphysician4-6weeksafterinitiation
http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-
Review.pdf
![Page 39: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/39.jpg)
SSRIAdverseEffects– Nausea,GIdiscomfort– Appetitechanges– Headaches– Dizziness– Insomnia– Activation– Bipolarswitching– Sexualdysfunction– Suicidalthinking– Vividdreams(teens)
http://www.glad-pc.org/
![Page 40: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/40.jpg)
SSRI’s• Contraindications
– Bipolardisorder– Psychosis
• Interactions/precautions– Cautionwithserotonergics
• TCAs,Lithium,Cocaine– Serotoninsyndrome
• Mentalstatuschanges• Autonomicinstability• Tremor,myoclonus
![Page 41: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/41.jpg)
Summary
• Considertherisksandbenefitsofmedication• Discussopenlywithpatientsandfamilies• Developaprocessforcontinuedmonitoring• Respondpromptlytoconcerns
![Page 42: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/42.jpg)
Ashley’s6yearoldbrother,Antwon,hasalsobeendiagnosedwithADHD.Heistaking
AdderallXR®,andsymptomshaveimproved.Hecontinuestohaveproblemswithrefusingtofollowdirections.Hetendstogetangryeasily.Heoftentriestogetbackatpeopleandcanbespiteful.Whenhismothertriestosetlimits,hehastantrumsthatlastforseveralminutes.Hismothernotesthatthingsathomehavebeen
verystressfulbecauseofhisbehavior.
![Page 43: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/43.jpg)
Antwon hasalsobeendiagnosedwithOppositionalDefiantDisorder.Hismotherdoesn’tknowifmoremedicationistherightchoice,butshedoesn’tknowwhatelsetodo.
Shefeelsthattheyare“attheendoftheirrope.”
IsmedicationappropriateforthetreatmentofOppositionalDefiantDisorder?
![Page 44: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/44.jpg)
OppositionalDefiantDisorder
• Behavioralinterventionsarefirstlinetreatment– Officebasedinterventions– Parenttrainingprograms
• IncredibleYears• ParentChildInteractionTraining• TriplePPositiveParentingProgram
AACAP. J Am Acad Child AdolescPsychiatr. 2007;46:126-141.
![Page 45: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/45.jpg)
OppositionalDefiantDisorder
• MedicationscanbeconsideredasadjunctivetreatmentbutareNOTcurative– MaximallytreatunderlyingADHDsymptomsfirst,ifpresent
– Useisoff-labelandnotwellstudied• Alpha-agonists• Atypicalantipsychoticmedications
– Impulsiveaggressionwithautism,mentalretardation
– ConsiderconsultationwithPPN
![Page 46: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/46.jpg)
AntipsychoticsOverview
• Antipsychoticmedicationsareusedtostabilizepatientsincrisis
• Symptomstargetedtypicallyinvolveaggressionand/ormania,possiblepsychosis
• Mostcommonfirstlinemedicationisrisperidoneoraripiprazole
• Secondlinemedicationmaybequetiapine
![Page 47: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/47.jpg)
AntipsychoticsandPrimaryCare
• StewardsofmedicalhealththatmaybeaffectedbyAntipsychoticmedications– MetabolicSyndrome:whentoconsiderMetformin
– Orthostaticeffects– Antihistaminergic effects– drymouth,constipation
• Needtounderstandthemedicalmonitoring• Actasabridge
![Page 48: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/48.jpg)
AntipsychoticSideEffects• Sedation• WEIGHTGAIN(evenaripiprazole)• Metaboliceffects
– Increasedglucose,insulinresistance,dyslipidemia(especiallyTG)
– Baseline:CBC,BMP,LFTs,FastingLipidsandGlucose– Every6months:Fastingglucoseandlipids,Hgb A1c
![Page 49: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/49.jpg)
AntipsychoticAdverseEffects
• Dystonia,Oculogyriccrisis,parkinsonism• Akathisia• WithdrawalDyskinesia• TardiveDyskinesia• Prolactinelevation
– Highestinrisperidone– Aripiprazolemaylowerit
• QTCprolongation(ziprasidone)
![Page 50: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/50.jpg)
AtypicalAntipsychoticMedications• Dramaticincreaseinprescribing
– Childreninfostercare– ChildrenwithSevereEmotionalDisturbance(SED)– ChildrenwithADHD
• Concerns– Safety– Questionableefficacy– Cost
![Page 51: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/51.jpg)
www.ohiomindsmatter.org
![Page 52: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/52.jpg)
UpdateonAntwon
• Antwon’smotherparticipatedinaparenttrainingprogramforchildrenwithdisruptivebehavior
• Antwon receivesadditionalschoolsupportsdesignedtoincreasedesirablebehavior
• YouworkwithAnton’sfamilytomaximizetreatmentofADHDsymptoms
![Page 53: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/53.jpg)
Summary
• Medicationscanbeaneffectivecomponentofacomprehensivetreatmentplan
• Evidence-informedresourcesareavailabletoguidecare– PediatricPsychiatryNetwork– OhioMindsMatter– E-LearningmodulesfromBuildingMentalWellness(BMW)
![Page 54: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/54.jpg)
References• AmericanAcademyofChildandAdolescentPsychiatry.Practiceparameterfortheassessmentand
treatmentofchildrenandadolescentswithAttention-DeficitHyperactivityDisorder.JAmAcad ChildAdolesc Psychiatr.2007;46:894-921.
• AmericanAcademyofChildandAdolescentPsychiatry.Practiceparameterfortheassessmentandtreatmentofchildrenandadolescentswithoppositionaldefiantdisorder.JAmAcad ChildAdolescPsychiatr.2007;46:126-141.
• CheungAH,Zuckerbrot RA,JensenPSetal.GuidelinesfortheAdolescentDepressioninPrimaryCare(GLAD-PC):II.TreatmentandOngoingManagement.Pediatrics.2007;120:e1313-e326.
• GibbonsRD,BrownCH,Hur K,etal.EarlyEvidenceontheEffectsofRegulators’Suicidality WarningsonSSRIPrescriptionsandSuicideinChildrenandAdolescents.AmJPsychiatry2007;164:1356–1363.
• Hammad TA.Reviewandevaluationofclinicaldata.Washington,DC,FoodandDrugAdministration,Aug16,2004(http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf).AccessedOctober22,2012.
• Pappadopulos E,MacIntyre JC,Crismon MLetal.Treatmentrecommendationsfortheuseofantipsychoticsforaggressiveyouth(TRAAY).PartII.JAmAcad ChildAdolesc Psychiatr.2003;42:145-161.
• Pliszka SR,Crismon ML,HughesCW,etal.TheTexasChildren’sMedicationAlgorithmProject:RevisionofthealgorithmforpharmacotherapyofAttention-Deficit-HyperactivityDisorder.JAmAcad ChildAdolescPsychiatr.2006;46:642-657.
• SubcommitteeonAttention-Deficit/HyperactivityDisorderandtheCommitteeonQualityImprovement.Clinicalpracticeguideline:treatmentoftheschool-agedchildwithAttention-Deficit/HyperactivityDisorder.Pediatrics.2001;108(4):1033-1044.
• SubcommitteeonAttention-Deficit/HyperactivityDisorder,SteeringCommitteeonQualityImprovementandManagement.ADHD:Clinicalpracticeguidelineforthediagnosis,evaluation,andtreatmentofAttention-Deficit/HyperactivityDisorderinchildrenandadolescents.Pediatrics.2011;128:1007-1022.
![Page 55: Evidence-Based Pharmacotherapy - ohioaap.orgohioaap.org/wp-content/uploads/2017/05/Pharmacotherapy_Harris_9-23... · Stahl SM. The Prescriber’s Guide. 3rd ed. New York, NY: Cambridge](https://reader031.vdocuments.us/reader031/viewer/2022030410/5a9a09127f8b9a30358db6dd/html5/thumbnails/55.jpg)
ADHDMedications
• Mostrecentguidancebasedonstrengthofevidence:
Methylphenidate~Amphetamine>>Atomoxetine
>LongactingGuanfacine>LongactingClonidine
AAP. Pediatrics. 2011;128:1007-22.